You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 260 No. 21, December 2, 1988 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Brief Reports
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (16)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antithymocyte Globulin Hypersensitivity in Bone Marrow Failure Patients

Leonard Bielory, MD; Ralph Wright, BSN; Arthur W. Nienhuis, MD; Neal S. Young, MD; Michael A. Kaliner, MD

JAMA. 1988;260(21):3164-3167.


Abstract

We evaluated the predictive value of immediate epicutaneous (prick) skin testing in 36 patients receiving a heterologous protein of equine origin, antithymocyte globulin (ATG), for bone marrow failure. Three of the 36 patients had positive epicutaneous test results. Two of these three received ATG treatment; one died of anaphylaxis while the other was desensitized successfully. Intradermal skin tests revealed positive wheal-flare reactions to progressively increasing dilutions of ATG in 96% of patients tested. None of these patients suffered any anaphylactic symptoms during treatment. Nine patients who had received ATG were evaluated subsequently for the possible development of immediate epicutaneous reactions three to 12 months after treatment; one of the nine patients developed a positive epicutaneous skin test reaction. We recommend that all patients who are to be treated or re-treated with heterologous antisera should be tested using the epicutaneous technique and that patients with positive reactions should be desensitized.

(JAMA 1988;260:3164-3167)



Author Affiliations

From the Division of Allergy and Immunology, the Department of Medicine, University of Medicine and Dentistry of New Jersey—New Jersey Medical School, Newark (Dr Bielory); the Allergic Diseases Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases (Dr Kaliner and Mr Wright), and the Cell Biology Section, Clinical Hematology Branch, National Heart, Lung, and Blood Institute (Drs Nienhuis and Young), National Institutes of Health, Bethesda, Md.


Footnotes

Reprint requests to Division of Allergy and Immunology, Department of Medicine, University of Medicine and Dentistry of New Jersey—New Jersey Medical School, 185 S Orange Ave, 1-512, Newark, NJ 07103-2757 (Dr Bielory).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Successful desensitization to antithymocyte globulin in a child with aplastic anemia.
Hall and Hagemann
Am J Health Syst Pharm 2006;63:1633-1636.
FULL TEXT  

Allergy and Immunology
Lockey and Bukantz
JAMA 1989;261:2824-2825.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.